Cost-effectiveness analysis of camrelizumab in the second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China

BACKGROUND: This study aimed to evaluate the cost-effectiveness of camrelizumab versus chemotherapy as second-line treatment for patients with advanced/metastatic esophageal squamous cell carcinoma (ESCC) from the perspective of the Chinese healthcare system. METHODS: A trial-based Markov model was...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Fan, Fu, Yu, Kumar, Arun, Chen, Mingsheng, Si, Lei, Rojanasarot, Sirikan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421963/
https://www.ncbi.nlm.nih.gov/pubmed/34532363
http://dx.doi.org/10.21037/atm-21-1803

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421963/
https://www.ncbi.nlm.nih.gov/pubmed/34532363
http://dx.doi.org/10.21037/atm-21-1803

Ejemplares similares